HYPERTENSION
BREAKTHROUGH
Dimas Fujiansyah
PHYSIOLOGY OF
BLOOD PRESSURE
01
INTRODUCTION
Peripheral resistance
Humoral factors
● Constrictors
○ Angiotensin II
○ Catecholamine
○ Thromboxane
○ Leukotrienes
○ Endothelin
● Dilators
○ Prostaglandins
○ Kinins
○ nitric oxide
Neuronal factors
● Constrictors
○ α-Adrenergics
● Dilators
○ β-Adrenergics
Cardiac output
Blood volume
● Sodium
● Mineralocorticoid
● Atrial natriuretic
peptide
Cardiac factors
● Heart rate
● Contractility
Blood Pressure Regulation: Hormones
Blood Pressure Regulation: Hormones
WHAT IS
HYPERTENSION ?
From the 2017 American College of Cardiology/American Heart Association, but there is some
controversy over this definition (Bell KJL, et al, JAMA Intern Med. 2018;178(6):755-757). Other
professional associations define hypertension as a systolic pressure diastolic pressure iety of
Hypertension (ISH), as well as the National Institute for Health and Care Excellence (NICE)
WHAT IS
HYPERTENSION ?
From the 2017 American College of Cardiology/American Heart Association, but there is some
controversy over this definition (Bell KJL, et al, JAMA Intern Med. 2018;178(6):755-757). Other
professional associations define hypertension as a systolic pressure diastolic pressure iety of
Hypertension (ISH), as well as the National Institute for Health and Care Excellence (NICE)
CLASSIFICATION
02
CLASSIFICATION
PRIMARY (IDIOPATHIC)
HYPERTENSION
SECONDARY
HYPERTENSION
Cumulative effects of several genetic
polymorphisms, environmental factors,
hypersensitive symphatic NS.
Renal artery stenosis,
Hyperaldosteronism,
Pheochromocytoma,
White Coat Hypertension
Diagnostics
● Blood pressure measurements several minutes
apart (after rest)
● Blood pressure measurements on several visits (at
least 2)
● Use 24-hour ambulatory Blood pressure monitoring
ETIOLOGY
03
ETIOLOGY
PRIMARY (IDIOPATHIC)
HYPERTENSION
● 25- 55 years old
● Hypersensitive
symphatetic nervous
system
● Cumulative effects of
several genetic
polymorphisms
● Interacting
environmental factors
SECONDARY HYPERTENSION
● Renal disorder
○ Renal Parencymal diseases
■ Damage on the stuctur of renal include collecting duct, t.
proximal, t. distal, etc.
○ Glomerulonephritis
○ DM nephropathy
○ polycystic kidney disease
● Renal vascular diseases
○ Stenosis > arterosclerosis renal artery
○ Inflamation > vasculitis
● Endocrine system
○ Adrenal gland
■ Khan syndrome
■ Cushing syndrome
■ pheocromocytoma
ETIOLOGY
SECONDARY HYPERTENSION
● Thyroid
○ Hyperthyroid
○ Hypothyroid
○ Hyperparathyroid
● Coarctation aorta
RISK FACTORS
05
RISK FACTORS
CLINICAL
MANIFESTATIONS
06
Signs and Symptoms
Asymptomatic until:
● Complications of
end-organ
damage arise
● An acute increase
in blood pressure
occurs
(hypertensive
crisis)
Signs and Symptoms
Nonspecific symptoms of hypertension
● Headaches (especially in the early morning or waking
headache)
● Flushed appearance
● Dizziness
● Tinnitus
● Blurred vision
PATHOPHYSIOLOGY
07
PATHOPHYSIOLOGY
PATHOPHYSIOLOGY
DIAGNOSIS
08
Diagnostic Criteria
The diagnosis of hypertension is made when at least three of the
following diagnostic criteria are met:
● Accurate measurement of BP
● Assessment of cardiovascular risk
● Assessment about secondary hypertension
TREATMENT
09
COMPLICATIONS
10
Cardiovascular System Complications
● Atherosclerosis
● Hypertensive heart disease
● Aortic aneurysm
● Aortic dissection
Brain Complications
● Stroke, transient ischemic attack (TIA)
Renal Complications
● Hypertensive nephrosclerosis
Ophthalmic Complications
● Hypertensive Retinopathy
PROGNOSIS
11
PROGNOSIS
● The prognosis depends on blood pressure control and is favorable
only if the blood pressures attain adequate control;
however, complications may develop in some patients as
hypertension is a progressive disease.
● Adequate control and lifestyle measures only serve to delay the
development and progression of sequelae such as chronic kidney
disease and renal failure.
EDUCATION
12
PROGNOSIS
● Detailed education regarding lifestyle modification and
pharmacological therapy is the key to success for better control of
blood pressure and to prevent complications.
● Weight management, physical activity, limiting
alcohol/tobacco/smoking is a critical strategy to decrease
cardiovascular risk
THANK
YOU
References
1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al.
2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the Management Of Arterial
Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens.
2018;36:1953–2041.
2. Global Burden of Disease Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84
behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories,
1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1923–1994.
3. Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A, Kruger R, Nilsson PM, Prabhakaran D, Ramirez AJ, et al,
MMM Investigators. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood
pressure by the International Society of Hypertension. Eur Heart J. 2019;40:2006–2017.
4. Beaney T, Schutte AE, Tomaszewski M, Ariti C, Burrell LM, Castillo RR, Charchar FJ, Damasceno A, Kruger R, Lackland DT, et
al. May Measurement Month 2017: an analysis of blood pressure screening results worldwide. Lancet Glob Health.
2018;6:e736-e743.
5. Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M.
Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults
and children. Can J Cardiol. 2018;34:506–525.

HYPERTENSION BREAKTHROUGH.pptx

  • 1.
  • 2.
  • 3.
  • 4.
    Peripheral resistance Humoral factors ●Constrictors ○ Angiotensin II ○ Catecholamine ○ Thromboxane ○ Leukotrienes ○ Endothelin ● Dilators ○ Prostaglandins ○ Kinins ○ nitric oxide Neuronal factors ● Constrictors ○ α-Adrenergics ● Dilators ○ β-Adrenergics
  • 5.
    Cardiac output Blood volume ●Sodium ● Mineralocorticoid ● Atrial natriuretic peptide Cardiac factors ● Heart rate ● Contractility
  • 6.
  • 7.
  • 8.
    WHAT IS HYPERTENSION ? Fromthe 2017 American College of Cardiology/American Heart Association, but there is some controversy over this definition (Bell KJL, et al, JAMA Intern Med. 2018;178(6):755-757). Other professional associations define hypertension as a systolic pressure diastolic pressure iety of Hypertension (ISH), as well as the National Institute for Health and Care Excellence (NICE)
  • 9.
    WHAT IS HYPERTENSION ? Fromthe 2017 American College of Cardiology/American Heart Association, but there is some controversy over this definition (Bell KJL, et al, JAMA Intern Med. 2018;178(6):755-757). Other professional associations define hypertension as a systolic pressure diastolic pressure iety of Hypertension (ISH), as well as the National Institute for Health and Care Excellence (NICE)
  • 10.
  • 11.
    CLASSIFICATION PRIMARY (IDIOPATHIC) HYPERTENSION SECONDARY HYPERTENSION Cumulative effectsof several genetic polymorphisms, environmental factors, hypersensitive symphatic NS. Renal artery stenosis, Hyperaldosteronism, Pheochromocytoma,
  • 12.
    White Coat Hypertension Diagnostics ●Blood pressure measurements several minutes apart (after rest) ● Blood pressure measurements on several visits (at least 2) ● Use 24-hour ambulatory Blood pressure monitoring
  • 13.
  • 14.
    ETIOLOGY PRIMARY (IDIOPATHIC) HYPERTENSION ● 25-55 years old ● Hypersensitive symphatetic nervous system ● Cumulative effects of several genetic polymorphisms ● Interacting environmental factors SECONDARY HYPERTENSION ● Renal disorder ○ Renal Parencymal diseases ■ Damage on the stuctur of renal include collecting duct, t. proximal, t. distal, etc. ○ Glomerulonephritis ○ DM nephropathy ○ polycystic kidney disease ● Renal vascular diseases ○ Stenosis > arterosclerosis renal artery ○ Inflamation > vasculitis ● Endocrine system ○ Adrenal gland ■ Khan syndrome ■ Cushing syndrome ■ pheocromocytoma
  • 15.
    ETIOLOGY SECONDARY HYPERTENSION ● Thyroid ○Hyperthyroid ○ Hypothyroid ○ Hyperparathyroid ● Coarctation aorta
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
    Asymptomatic until: ● Complicationsof end-organ damage arise ● An acute increase in blood pressure occurs (hypertensive crisis)
  • 21.
    Signs and Symptoms Nonspecificsymptoms of hypertension ● Headaches (especially in the early morning or waking headache) ● Flushed appearance ● Dizziness ● Tinnitus ● Blurred vision
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
    Diagnostic Criteria The diagnosisof hypertension is made when at least three of the following diagnostic criteria are met: ● Accurate measurement of BP ● Assessment of cardiovascular risk ● Assessment about secondary hypertension
  • 29.
  • 31.
  • 32.
    Cardiovascular System Complications ●Atherosclerosis ● Hypertensive heart disease ● Aortic aneurysm ● Aortic dissection
  • 33.
    Brain Complications ● Stroke,transient ischemic attack (TIA)
  • 34.
  • 35.
  • 36.
  • 37.
    PROGNOSIS ● The prognosisdepends on blood pressure control and is favorable only if the blood pressures attain adequate control; however, complications may develop in some patients as hypertension is a progressive disease. ● Adequate control and lifestyle measures only serve to delay the development and progression of sequelae such as chronic kidney disease and renal failure.
  • 38.
  • 39.
    PROGNOSIS ● Detailed educationregarding lifestyle modification and pharmacological therapy is the key to success for better control of blood pressure and to prevent complications. ● Weight management, physical activity, limiting alcohol/tobacco/smoking is a critical strategy to decrease cardiovascular risk
  • 40.
  • 41.
    References 1. Williams B,Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the Management Of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041. 2. Global Burden of Disease Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1923–1994. 3. Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A, Kruger R, Nilsson PM, Prabhakaran D, Ramirez AJ, et al, MMM Investigators. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J. 2019;40:2006–2017. 4. Beaney T, Schutte AE, Tomaszewski M, Ariti C, Burrell LM, Castillo RR, Charchar FJ, Damasceno A, Kruger R, Lackland DT, et al. May Measurement Month 2017: an analysis of blood pressure screening results worldwide. Lancet Glob Health. 2018;6:e736-e743. 5. Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M. Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34:506–525.